<DOC>
	<DOCNO>NCT02625480</DOCNO>
	<brief_summary>This single arm , open-label , multi-center , phase 1/2 study , determine safety efficacy KTE-C19 , autologous anti-CD19 chimeric antigen receptor ( CAR ) -positive T cell therapy , relapsed/refractory B-precursor acute lymphoblastic leukemia ( ALL ) pediatric adolescent subject .</brief_summary>
	<brief_title>A Multi-Center Study Evaluating KTE-C19 Pediatric Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>1 . Relapsed refractory Bprecursor ALL define one following : Primary refractory disease Relapsed refractory disease first later salvage therapy Relapsed refractory disease allogeneic transplant provide subject least 100 day stem cell transplant time enrollment 2 . Morphological disease bone marrow ( ≥ 5 % blast ) 3 . Subjects Ph+ disease eligible intolerant tyrosine kinase inhibitor ( TKI ) therapy , relapsed/refractory disease despite treatment least 2 different TKIs 4 . Ages 2 21 time Assent Consent per IRB guideline 5 . Lansky ( age &lt; 16 year time assent/consent ) Karnofsky ( age ≥ 16 year time assent/consent ) performance status ≥ 80 screen 6 . Adequate renal , hepatic , pulmonary cardiac function define : Creatinine clearance ≥ 60 cc/min Serum ALT/AST ≤ 2.5 x ULN Total bilirubin ≤ 1.5 x ULN Cardiac ejection fraction ≥ 50 % clinically significant ECG finding Baseline oxygen saturation &gt; 92 % room air Exclusion Criteria 1 . Diagnosis Burkitt 's leukemia/lymphoma accord WHO classification chronic myelogenous leukemia lymphoid blast crisis 2 . History malignancy nonmelanoma skin cancer carcinoma situ ( e.g . cervix , bladder , breast ) unless disease free least 3 year 3 . Presence CNS3 disease CNS2 disease neurological change 4 . History concomitant genetic syndrome Fanconi anemia , Kostmann syndrome , ShwachmanDiamond syndrome know bone marrow failure syndrome 5 . History myocardial infarction , cardiac angioplasty stenting , unstable angina , clinically significant cardiac disease within 12 month enrollment 6 . History symptomatic deep vein thrombosis pulmonary embolism within 6 month enrollment . 7 . Primary immunodeficiency 8 . Known infection HIV , hepatitis B ( HBsAg positive ) hepatitis C virus ( antiHCV positive ) 9 . Presence fungal , bacterial , viral , infection uncontrolled require IV antimicrobial management . 10 . Prior medication : Prior CD19 direct therapy , include CAR+ T cell , BiTE , antibody drug conjugate ( ADC ) , exception subject receive KTEC19 study eligible retreatment Treatment alemtuzumab within 6 month prior leukapheresis , treatment clofarabine cladribine within 3 month prior leukapheresis Donor lymphocyte infusion ( DLI ) within 28 day prior enrollment Any drug use GVHD within 4 week prior enrollment 11 . Acute GVHD grade IIIV Glucksberg criterion severity BD IBMTR index ; acute chronic GVHD require systemic treatment within 4 week prior enrollment 12 . Live vaccine ≤ 6 week prior start condition regimen 13 . Women childbearing potential pregnant breastfeed potentially dangerous effect preparative chemotherapy fetus infant . Females undergone surgical sterilization consider childbearing potential 14 . Subjects gender childbearing potential willing practice birth control time consent 6 month completion KTEC19</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>